US20210361621A1 - Compositions and Methods for Reducing Weight Gain - Google Patents
Compositions and Methods for Reducing Weight Gain Download PDFInfo
- Publication number
- US20210361621A1 US20210361621A1 US17/393,000 US202117393000A US2021361621A1 US 20210361621 A1 US20210361621 A1 US 20210361621A1 US 202117393000 A US202117393000 A US 202117393000A US 2021361621 A1 US2021361621 A1 US 2021361621A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- reutericyclin
- weight gain
- composition
- risperidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004584 weight gain Effects 0.000 title claims abstract description 58
- 235000019786 weight gain Nutrition 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 38
- USPHRMIDXYGOBA-HQUFOCMISA-N (2r)-1-[(e)-dec-2-enoyl]-5-hydroxy-4-(1-hydroxyethyl)-2-(2-methylpropyl)pyrrolidin-3-one Chemical compound CCCCCCC\C=C\C(=O)N1C(O)C(C(C)O)C(=O)[C@H]1CC(C)C USPHRMIDXYGOBA-HQUFOCMISA-N 0.000 claims abstract description 62
- QHXAUDQIMHYILR-UHFFFAOYSA-N Reutericyclin Natural products CCCCCCCC=CC(=O)N1C(CC(C)C)C(=O)C(=C1O)C(=O)C QHXAUDQIMHYILR-UHFFFAOYSA-N 0.000 claims abstract description 61
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 44
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 24
- 230000003115 biocidal effect Effects 0.000 claims abstract description 18
- 239000002676 xenobiotic agent Substances 0.000 claims abstract description 18
- 230000002034 xenobiotic effect Effects 0.000 claims abstract description 18
- 230000004580 weight loss Effects 0.000 claims abstract description 15
- 229960001534 risperidone Drugs 0.000 claims description 40
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 18
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 229940124604 anti-psychotic medication Drugs 0.000 claims description 13
- 239000006166 lysate Substances 0.000 claims description 13
- -1 Trimethroprim Chemical compound 0.000 claims description 12
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 11
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 10
- 229960005017 olanzapine Drugs 0.000 claims description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 10
- 229960004099 azithromycin Drugs 0.000 claims description 8
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229960003276 erythromycin Drugs 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 239000004099 Chlortetracycline Substances 0.000 claims description 5
- 108010059993 Vancomycin Proteins 0.000 claims description 5
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004475 chlortetracycline Drugs 0.000 claims description 5
- 235000019365 chlortetracycline Nutrition 0.000 claims description 5
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 229960004431 quetiapine Drugs 0.000 claims description 5
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 5
- 229960005322 streptomycin Drugs 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 claims description 4
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 claims description 4
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 4
- 108010001478 Bacitracin Proteins 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 229930182566 Gentamicin Natural products 0.000 claims description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- 239000004104 Oleandomycin Substances 0.000 claims description 4
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004100 Oxytetracycline Substances 0.000 claims description 4
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004182 Tylosin Substances 0.000 claims description 4
- 229930194936 Tylosin Natural products 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 4
- 229960000723 ampicillin Drugs 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 229960003071 bacitracin Drugs 0.000 claims description 4
- 229930184125 bacitracin Natural products 0.000 claims description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 4
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 claims description 4
- 229960005361 cefaclor Drugs 0.000 claims description 4
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 4
- 229960004841 cefadroxil Drugs 0.000 claims description 4
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 4
- 229960003719 cefdinir Drugs 0.000 claims description 4
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 4
- 229960002100 cefepime Drugs 0.000 claims description 4
- 229960002129 cefixime Drugs 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- 229960002682 cefoxitin Drugs 0.000 claims description 4
- 229960005090 cefpodoxime Drugs 0.000 claims description 4
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 4
- 229960002580 cefprozil Drugs 0.000 claims description 4
- 229960000484 ceftazidime Drugs 0.000 claims description 4
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 4
- 229960004086 ceftibuten Drugs 0.000 claims description 4
- 229960004755 ceftriaxone Drugs 0.000 claims description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 4
- 229960001668 cefuroxime Drugs 0.000 claims description 4
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 4
- 229940106164 cephalexin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims description 4
- 229960002626 clarithromycin Drugs 0.000 claims description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 4
- 229960002227 clindamycin Drugs 0.000 claims description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 4
- 229960004170 clozapine Drugs 0.000 claims description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 4
- 235000019374 flavomycin Nutrition 0.000 claims description 4
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 4
- 229960002518 gentamicin Drugs 0.000 claims description 4
- 229960002182 imipenem Drugs 0.000 claims description 4
- 229960003376 levofloxacin Drugs 0.000 claims description 4
- 229960003907 linezolid Drugs 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229960001977 loracarbef Drugs 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229940041033 macrolides Drugs 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 229940053050 neomycin sulfate Drugs 0.000 claims description 4
- 229960002351 oleandomycin Drugs 0.000 claims description 4
- 235000019367 oleandomycin Nutrition 0.000 claims description 4
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 claims description 4
- 229960000625 oxytetracycline Drugs 0.000 claims description 4
- 235000019366 oxytetracycline Nutrition 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- 229960000652 sertindole Drugs 0.000 claims description 4
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000654 sulfafurazole Drugs 0.000 claims description 4
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000707 tobramycin Drugs 0.000 claims description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 4
- 229960004059 tylosin Drugs 0.000 claims description 4
- 235000019375 tylosin Nutrition 0.000 claims description 4
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims description 4
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 3
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 3
- 229950007118 bambermycin Drugs 0.000 claims description 3
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 claims 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 34
- 235000018291 probiotics Nutrition 0.000 abstract description 34
- 238000011282 treatment Methods 0.000 abstract description 34
- 230000000529 probiotic effect Effects 0.000 abstract description 32
- 241000124008 Mammalia Species 0.000 abstract description 7
- 208000021017 Weight Gain Diseases 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 241000282412 Homo Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 5
- 238000007637 random forest analysis Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 3
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 3
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 3
- 241000702462 Akkermansia muciniphila Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- SSWTVBYDDFPFAF-DKOGRLLHSA-N ceftibuten dihydrate Chemical compound O.O.S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 SSWTVBYDDFPFAF-DKOGRLLHSA-N 0.000 description 3
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940054010 other antipsychotics in atc Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- TUPFOYXHAYOHIB-WZGOVNIISA-M sodium;(2s,5r,6r)-6-[[(2s)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]h Chemical compound [Na+].C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 TUPFOYXHAYOHIB-WZGOVNIISA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RUXHWBMJNBBYNL-UHFFFAOYSA-N 3-hydroxy-1,2-dihydropyrrol-5-one Chemical compound OC1=CC(=O)NC1 RUXHWBMJNBBYNL-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- PMXMIIMHBWHSKN-LJQANCHMSA-N (R)-paliperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCC[C@@H](O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-LJQANCHMSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940100627 bambermycins Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940036674 latuda Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940042084 saphris Drugs 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- a method of reducing weight gain or reversing weight gain in a human or another mammal can comprise or consist essentially of administering a therapeutically effective amount of reutericyclin to reduce weight gain or induce weight loss using a clinically accepted administration route.
- the human or another mammal is being treated with an antibiotic or xenobiotic.
- the therapeutically effective amount of reutericyclin can be co-administered with an antibiotic or xenobiotic.
- the xenobiotic can be an antipsychotic medication.
- the antipsychotic medication can be selected from the group consisting of risperidone, clozapine, olanzapine, quetiapine, sertindole, and lithium.
- the antibiotic can be Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim, Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin.
- Macrolides Azithromycin, Clarithromycin, Erythromycin, chlortetracycline, procaine, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, vancomycin, virginamycin, and bambermycin.
- the mode of administration can be oral.
- a method of reducing weight gain or reversing weight gain in a human or another mammal can comprise or consist essentially of administering a therapeutically effective amount of reutericyclin-producing strain of Lactobacillus reuterii to reduce weight gain or induce weight loss using a clinically accepted administration route.
- the reutericyclin-producing strain can be L. reuteri LTH2584.
- the human or another mammal can be receiving treatment with an antibiotic or xenobiotic.
- the therapeutically effective amount of reutericyclin can be co-administered with an antibiotic or xenobiotic.
- the xenobiotic can be an antipsychotic medication.
- the antipsychotic medication can be selected from the group consisting of risperidone, clozapine, olanzapine, quetiapine, and sertindole.
- the antibiotic can be Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim, Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, S
- Macrolides Azithromycin, Clarithromycin, Erythromycin, chlortetracycline, procaine, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, vancomycin, virginamycin, and bambermycin.
- the mode of administration can be oral.
- a pharmaceutical composition comprising Lactobacillus reuterii LTH2584 or a lysate thereof.
- the pharmaceutical composition can further comprise a probiotic bacterium of a strain other than L. reuteri LTH2584, or a lysate thereof, and pharmaceutically acceptable carrier.
- the Lactobacillus reuterii LTH2584 can be present in the composition at a quantity of at least 1,000,000 colony forming units per gram, based upon the total weight of the composition.
- a lysate of Lactobacillus reuterii LTH2584 is provided herein.
- FIG. 1 demonstrates that Lactobacillus reuterii is selectively depleted in risperidone-treated mice.
- Shotgun metagenomic sequencing data (MiSeq, 2 ⁇ 250, high yield) from stool DNA was analyzed on the Anvi'o visualization platform.
- Bacterial genomes were refined to either genus or species level and ordered as slices within a ring by gene similarity (hierarchical clustering with a Hidden Markov Model). Metagenome groups enriched following risperidone treatment are indicated (red) relative to controls (blue).
- FIGS. 2A-2C show that supplementation with reutericyclin-producing strain LTH2584 abrogates weight gain in mice.
- B Shown are body mass increases for control animals (blue), those receiving L. reuteri producing reutericyclin (green), or L. reuteri producing reutericyclin+risperidone (magenta), or L. reuteri unable to produce reutericyclin+risperidone (red).
- FIG. 3 Random Forest model classifies olanzapine-treated mice as well as risperidone based on changes in key taxa.
- FIG. 4 Linear model (LM) predictions against the actual weight gained for risperidone, reutericyclin, and probiotic treated mice.
- the randomized training set animals are shown in black and the test set animals are shown in blue.
- FIG. 5 Linear model (LM) predicts the weight gain in olanzapine-treated animals (p ⁇ 0.00001).
- FIG. 6 Detection of unique genes in Akkermansia muciniphila found in probiotic-treated animals can be adapted to a PCR-based test for treatment efficacy.
- compositions and methods provided herein are based, at least in part, on the inventors' surprising discovery that reutericyclin, a small molecular weight antimicrobial produced by some strains of Lactobacillus reuteri .
- the present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing Lactobacillus reuterii bacteria as a probiotic to reduce weight gain or to induce weight loss, particularly for subjects receiving an antibiotic or xenobiotic treatment.
- Microbes that inhabit the human gastrointestinal (GI) tract are involved in xenobiotic processing, as evidenced by changes in metabolism in the absence of microbes (i.e., germ-free (GF) animals) or upon microbial perturbation (i.e., antibiotic treatment or dietary modulation).
- microbial perturbation i.e., antibiotic treatment or dietary modulation.
- supplementation with reutericyclin, an analog thereof, or reutericyclin-producing Lactobacillus reuterii may induce and/or support beneficial weight loss, particularly in subject receiving treatment with an antibiotic or pharmaceutical that alters metabolism and is linked to weight gain or obesity.
- reutericyclin refers to a highly hydrophobic, charged tetramic acid molecule produced by and isolated from particular strains of Lactobacillus reuterii .
- reutericyclin is (5R)-1-(2-decenoyl)-2-hydroxy-3-acetyl-5-isobutyl- ⁇ 2-pyrroline-4-one, a N-acylated tetramic acid.
- N-alkyl reutericyclin analogs have been shown to retain activity against Gram-positive pathogens and other functional properties of reutericyclin. See, e.g., Yendapally et al., J. Med. Chem. 51, 1487-1491 (2008); Hurdle et al., Antimicrob. Agents Chemother. 53, 4028-4031 (2009).
- the method comprises administering a therapeutically effective amount of reutericyclin to reduce weight gain or induce weight loss using a clinically accepted administration route.
- reutericyclin can also be co-administered (e.g., sequentially or simultaneously) with or following administration of such an antibiotic or xenobiotic in order to preserve non-pathological intestinal bacterial flora in the subject to whom the reutericyclin is administered.
- xenobiotic refers to chemical compounds to which an organism (e.g., human, non-human mammal) is exposed that are extrinsic to the normal metabolism of that organism.
- the term encompasses synthetic drugs, small molecules, natural poisons, food additives, environmental pollutants, antibiotics, and other pharmaceuticals.
- antibiotic refers to a chemotherapeutic substance that is capable of killing and inhibiting growth of specific microorganisms, such as infectious bacteria and fungi. Antibiotics are classified based on their mechanism of action (i.e., if on the cell membrane, cell wall, or metabolism), chemical structure, spectrum of activity (i.e., if targeting gram-negative or gram-positive bacteria), or by mode of administration (e.g. oral, intravenous, or topical).
- reducing refers to any indicia of success in the prevention or reduction of weight gain in a patient induced by or associated with an antibiotic or xenobiotic medication.
- the prevention or reduction of weight gain can be measured based on objective parameters, such as the results of a physical examination.
- reversing refers to any indicia of success in causing the loss of antibiotic- or xenobiotic-associated weight gain established prior to the administration of reutericyclin or an analog thereof.
- the reduction of weight already gained can be measured based on objective parameters, such as the results of a physical examination.
- Pharmaceuticals known to be associated with weight gain in patients receiving the medication include, without limitation antibiotics, antipsychotic medications (e.g., risperidone, haloperidol, olanzapine, clozapine, quetiapine, sertindole, and lithium), antidepressants (e.g., amitriptyline, paroxetine, and sertraline), oral corticosteroids, and drugs for treating diabetes and pre-diabetes (e.g., pre-diabetic states of impaired glucose tolerance) or its associated complications.
- antipsychotic medications e.g., risperidone, haloperidol, olanzapine, clozapine, quetiapine, sertindole, and lithium
- antidepressants e.g., amitriptyline, paroxetine, and sertraline
- oral corticosteroids e.g., and drugs for treating diabetes and pre-dia
- the methods and compositions provided herein are particularly advantageous to reduce weight gain or reverse weight gain in subjects to whom an antipsychotic medication such as risperidone or another atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives.
- Risperidone has been shown to alter the gut microbiome and suppress non-aerobic resting metabolism in mice receiving the antipsychotic medication (Bahr et al., EBioMedicine 2:1725-1734 (2015)).
- Bahr et al. demonstrated that risperidone treatment led to an overall reduction in observed taxa in the gut microbiome and selectively suppressed growth of organisms under anaerobic conditions.
- weight gain examples include, without limitation, quetiapine (Seroquel), paliperidone (invega), iloperidone (Fanapt), olanzapine (zyprexa), asenapine (saphris), lurasidone (latuda).
- Antibiotics known to cause weight gain in farm animals and used in animal feed include, without limitation, chlortetracycline, procaine, penicillin, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, virginamycin, and bambermycins.
- Antibiotics known to induce weight gain in mice include, without limitation, chlortetracycline, penicillin, vancomycin, combinations of penicillin and vancomycin, streptomycin, and ciprofloxacin.
- antibiotics listed by category are correlated with weight gain in humans. These associations have not been established via clinical trials, but are associated with either adult or pediatric exposure to antibiotics and the recipient's risk of developing obesity later in life. Taking any of the antibiotics listed either long term or single dose increases risk of developing obesity by 10-15%.
- Narrow-spectrum antibiotics Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim.
- Broad-spectrum antibiotics Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin. Macrolides: Azithromycin, Clarithromycin, Erythromycin.
- body fat means a medical condition in which excess body fat has accumulated to the extent that it may have a negative effect on health.
- body fat is the body mass index (BMI), a measurement that compares weight and height, defines obesity as greater than 30 kg (weight) per m 2 (height 2 ). Obesity increases the likelihood of various diseases, particularly heart disease and type 2 diabetes (T2D).
- BMI body mass index
- T2D type 2 diabetes
- a “therapeutically effective amount” means an amount of a compound or composition that, when administered to a subject for treating a disorder, condition, or disease, is sufficient to effect such treatment for the disorder, or condition, or disease.
- the “therapeutically effective amount” will vary depending on the compound or composition, the disorder, or condition, or disease state being treated, the severity or the disorder, or condition, or disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
- the dosage schedule and amounts effective for this use i.e., the “dosing regimen,” will depend upon a variety of factors, including the type of the medication the patient is using, the amount of pharmaceutical-induced weight gain that has already occurred, the patient's physical status, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
- the mode of administration also is taken into consideration.
- a probiotic composition including an appropriate quantity of reutericyclin-producing Lactobacillus reuteri bacteria, as well as methods for using the disclosed probiotic composition to induce and sustain weight loss in humans and non-human mammals, such as humans, horses, rats, mice, ruminants, primates, monkeys, hamsters, rabbits, and cats.
- probiotic refers to a live or dead microbial food supplement which beneficially affects the animal, including human host by improving the individual's microbial balance in the gastrointestinal tract, e.g., Lactobacillus reuteri and other Lactobacillus acidophilus .
- a probiotic microorganism is useful for changing the digestive system bacteria in animals when fed orally.
- a probiotic microorganism upon oral feeding, sustain or increase the population of appropriate Bacteroides bacteria in the gastrointestinal tract of the host. It is believed that successful establishment and propagation of appropriate reutericyclin-producing Lactobacillus reuteri bacteria in the gastrointestinal tract of a subject may induce and/or support beneficial weight loss, particularly in humans.
- the probiotic microorganism remains effective in the digestive system for substantial periods of time even after oral feeding is discontinued.
- Lactobacillus reuteri is one of the few endogenous Lactobacillus species found in the gastrointestinal tract of vertebrates, including humans, rats, pigs and chickens.
- Reutericyclin-producing strains of Lactobacillus reuteri suitable for the compositions and methods provided herein include, without limitation, Lactobacillus reuterii LTH2584, Lactobacillus reuterii TMW1.106, Lactobacillus reuterii 1.112, and Lactobacillus reuterii 1.656. Each of these strains was isolated from the same industrial sourdough in 1988, 1994, and 1998, which has been maintained by continuous propagation.
- the reutericyclin-producing bacteria are L. reuteri LTH2584.
- probiotic bacteria or their lysates according to the invention may be formulated as pharmaceutical compositions for clinical use and may comprise a pharmaceutically acceptable carrier, diluent or adjuvant.
- lysates refers to a sample of the probiotic bacterium which has been subject to lysis. A lysate may contain one or more soluble metabolites of the probiotic bacterium useful in the methods described herein.
- Lysis may occur by chemical or physical disruption, for example by addition of an osmotic agent or enzyme to the bacteria, or by the application of physical pressure, for example through sonic disruption.
- the lysate may be a mixture comprising the cellular contents of the probiotic bacterium. For example, one or more of fragments of cell wall or cell membrane, proteins, nucleic acids, carbohydrates, and organelles (disrupted or intact).
- the lysate may be suspended, for example in aqueous medium.
- reutericyclin-producing Lactobacillus reuteri bacteria are co-administered with or following administration of an antibiotic or xenobiotic to a subject in need thereof in order to preserve non-pathological intestinal bacterial flora in the subject to whom the reutericyclin-producing L. reuteri are administered.
- reutericyclin-producing Lactobacillus reuteri bacteria are provided as a probiotic in foods, medicines for humans and animals, and feedstock.
- probiotic reutericyclin-producing Lactobacillus reuteri bacteria are used alone, with an appropriate vehicle (carrier), or as an additive to a foodstuff or other composition suitable for human or animal (e.g., livestock, household pets) consumption.
- the reutericyclin-producing Lactobacillus reuteri bacteria are useful because it can be added both to foodstuffs that do not contain probiotic bacteria (for the purpose of giving these products a probiotic value as well) and to foodstuffs already containing some probiotic bacteria (for the purpose of enhancing and/or completing their probiotic value).
- livestock includes swine, cow, horse, goat, sheep, etc.; poultry includes fowls such as chicken, etc.; and pets include dogs, cats, etc.
- treating describes the management and care of a patient for the purpose of combating the disease, condition, or disorder.
- the terms embrace both preventative, i.e., prophylactic, and palliative treatments. Treating includes the administration of a composition as described herein to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- subject refers to an animal or a patient for whom the described treatment is intended.
- subjects treated according to the methods provided herein are mammals, including by way of example and not limitation, members of rodentia (e.g., mouse, rat, guinea pig), lagomorpha (e.g., rabbits, hares), perissodactyla (e.g., horses, donkeys, etc.), artodactyla (e.g., pigs, cows, sheep), carnivora (e.g., cats, canines), and primates (e.g., apes, monkeys, baboons, and humans).
- rodentia e.g., mouse, rat, guinea pig
- lagomorpha e.g., rabbits, hares
- perissodactyla e.g., horses, donkeys, etc.
- artodactyla e.g., pigs, cow
- a rodent e.g., mouse, rat
- a primate e.g., a monkey, baboon, human
- the subject is a human.
- the term “subject” does not denote a particular age or sex.
- subject in need thereof we mean an animal or human subject who has been diagnosed with a disease or condition requiring treatment.
- reutericyclin or reutericyclin-producing bacteria are administered to a subject as a pharmaceutical composition and in an effective amount to treat and/or prevent a disorder (e.g., weight gain) as described herein.
- the pharmaceutical composition comprises probiotic bacteria of the strain Lactobacillus reuterii LTH2584.
- the probiotic bacteria may be provided in the form of a lysate.
- a lysate of probiotic bacteria may be subjected to purification of filtration steps to remove other components, such as bacterial growth media or contaminants.
- the term “pharmaceutical composition” refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof, with other chemical components, such as physiologically acceptable carriers and excipients.
- a pharmaceutical composition is to facilitate administration of a compound to an organism.
- a “pharmaceutically acceptable carrier” refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- “Pharmaceutically acceptable salt” refers to those salts that retain the biological effectiveness and properties of the free bases and that are obtained by reaction with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- compositions and dosage forms of the disclosure include a pharmaceutically acceptable salt of disclosed or a pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof.
- Specific salts of disclosed compounds include, but are not limited to, sodium, lithium, potassium salts, and hydrates thereof. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in Handbook of Pharmaceutical Salts: Properties, and Use (2002), which is incorporated herein by reference.
- compositions can be administered to a subject in need thereof in dosage unit form where each discrete dosage unit contains a predetermined quantity of an active ingredient or compound that was calculated to elicit a desirable therapeutic effect when administered with, in some cases, a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers refers to carriers, excipients, or stabilizers that are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as g
- pharmaceutically acceptable carriers are particularly important to protect and preserve the probiotic bacteria until such time that the probiotic bacteria arrive within the gastrointestinal tract of a subject.
- a therapeutically effective dose it can be advantageous to assess toxicity and therapeutic efficacy of a compound (e.g., reutericyclin or an analog thereof) in an in vitro assay (e.g., cell cultures) or in experimental animals.
- a compound e.g., reutericyclin or an analog thereof
- the LD 50 i.e., the dose lethal to 50% of the population
- ED 50 i.e., the dose therapeutically effective in 50% of the population
- dosage ranges for use in humans can be formulated. Dosage ranges can vary depending on factors such as mode of administration.
- a therapeutically effective amount of a pharmaceutical composition provided herein can range from about 0.001 to 100 mg of an active ingredient per kg body weight of the subject (e.g., about 0.001 to 100 mg/kg body weight; about 0.1 to 40 mg/kg body weight; about 1 to 20 mg/kg body weight).
- an appropriate dose of a pharmaceutical composition can be determined according to body surface area of a subject, calculated using the subject's height and weight, to whom the composition will be administered. In such cases, a dose can be provided as a particular amount of the composition per m 2 (e.g., mg/m 2 ).
- dosages and dosage ranges appropriate for a composition provided herein can be determined using pharmacokinetic data (i.e., drug metabolism and clearance).
- “pharmacokinetics” refers to the process by which a drug or pharmaceutical composition is absorbed, distributed, metabolized, and excreted from the body. Additional information about dosage calculation can be found in Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2002), Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, U.S. Food and Drug Administration, Rockville, Md., USA.
- a therapeutically effective dose level will depend on many factors.
- Efficacy of the methods provided herein can be determined using any appropriate method. For example, weight gain may be determined and evaluated with any one of several objective, standard instruments known in the art, which include scales and instruments that measure body fat percentage. The simple instrument of a scale is routinely used by all professional health care practitioners. More sophisticated instruments to measure body fat percentage operate based on skin-fold methodology and measurement of body density or electrical resistance.
- a formulation may contain a single (unit) dose of probiotic bacteria, or lysate thereof.
- Suitable doses of probiotic bacteria may be in the range 10 4 to 10 12 colony forming units (cfu), e.g. one of 10 4 to 10 10 , 10 4 to 10 8 , 10 6 to 10 12 , 10 6 to 10 10 , or 10 6 to 10 8 cfu.
- doses may be administered once or twice daily.
- Pharmaceutical unit dosage forms of the compounds of this disclosure are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., bolus injection), topical, or transdermal administration to a patient.
- mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
- parenteral e.g., bolus injection
- topical e.g., bolus injection
- dosage forms include, but are not limited to: tablets; caplets; capsules, such as hard gelatin capsules and soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
- suspensions e.g.,
- compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology , eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- compositions, shape, and type of dosage forms of the compositions of the disclosure will typically vary depending on their use.
- a dosage form used in the acute treatment of a disease or disorder may contain larger amounts of the active ingredient, for example the disclosed compounds or combinations thereof, than a dosage form used in the chronic treatment of the same disease or disorder.
- a parenteral dosage form may contain smaller amounts of the active ingredient than an oral dosage form used to treat the same disease or disorder.
- Clinicians, physicians, and other health care professionals can administer a composition to a subject in need thereof according to a method provided herein.
- a single administration of the composition may be sufficient.
- more than one administration of the composition is performed at various intervals (e.g., once per week, twice per week, daily, monthly) or according to any other appropriate treatment regimen.
- the duration of treatment can be a single dose or periodic multiple doses for as long as administration of a composition provided herein is tolerated by the subject.
- mice were treated with L. reuteri producing reutericyclin, with or without risperidone treatment.
- 8-week old C57Bl/6J female mice were treated daily via gavage with 100 ⁇ L containing either 3 ⁇ 10 8 CFUs of Lactobacillus reuterii strain LTH2584 (a reutericyclin-producing strain) or buffer (phosphate buffered saline). Drinking water was supplemented with buffer or risperidone (20 mg/mL).
- FIG. 2B shows body mass increases for control animals (green), those receiving L. reuteri producing reutericyclin (blue), or L. reuteri producing reutericyclin+risperidone (magenta), or L. reuteri unable to produce reutericyclin+risperidone (red).
- Animals receiving risperidone only were nearly identical to the red line (data not shown).
- Weight gain in mice treated with risperidone plus L. reuteri producing reutericyclin (magenta) is abrogated at 64 days of treatment relative to those animals receiving risperidone plus L. reuteri lacking the capability to produce reutericyclin (red) as determined by Wilcoxon (*p ⁇ 0.05), yet showed some weight gain relative to control animals (green) or bacteria-only treated mice (blue).
- Visceral fat pads were dissected at day 64 from each mouse, weighed, and quantified. As shown in FIG. 2C , fat pads from risperidone treated mice that also received L. reuteri capable of producing reutericyclin were significantly reduced relative to those animals that received risperidone treatment alone (Wilcoxon, *p ⁇ 0.05).
- a set of taxonomic changes that characterize the microbiomes of risperidone-treated animals and reutericyclin-treated animals was identified. Using a machine learning method known as Random Forest (RF), these differences were used to generate a prediction model. The minimal components of the model and their relative importance are shown in FIG. 3 .
- a classifier for treatment response and a linear model of weight gain in response to these treatments based on gene-specific differences.
- Akkermansia muciniphila strains have unique 26.1 kb genomic signature in risperidone-treated animals compared to probiotic LTH2584 treated animals.
- Akkermansia muciniphila has a unique 37.8 kb stretch ( FIG. 6 ) in LTH2584 probiotic treated animals.
- a PCR-based test can be generated to identify these genes in order to determine treatment efficacy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing Lactobacillus reuterii bacteria as a probiotic to reduce weight gain or to induce weight loss, particularly for subjects receiving an antibiotic or xenobiotic treatment.
Description
- This patent application is a continuation of U.S. application Ser. No. 16/511,630 filed on Jul. 15, 2019, which claims the benefit of priority of U.S. Provisional Patent Application No. 62/698,601, filed on Jul. 16, 2018, the contents of which are incorporated herein by reference in their entireties.
- Not applicable.
- Excessive weight gain associated with use of various medications including antibiotics and antipsychotic medications is a significant issue given its impact on general health. Unwanted weight gain and metabolic changes are some of the most common reasons for a patient's non-compliance with a treatment regimen, ultimately leading to the failure of the treatment. Accordingly, it would be desirable to identify and develop more effective compositions and methods to reduce or reverse weight gain associated with changes to the gut microbiome.
- In a first aspect, provided herein is a method of reducing weight gain or reversing weight gain in a human or another mammal. The method can comprise or consist essentially of administering a therapeutically effective amount of reutericyclin to reduce weight gain or induce weight loss using a clinically accepted administration route. The human or another mammal is being treated with an antibiotic or xenobiotic. The therapeutically effective amount of reutericyclin can be co-administered with an antibiotic or xenobiotic. The xenobiotic can be an antipsychotic medication. The antipsychotic medication can be selected from the group consisting of risperidone, clozapine, olanzapine, quetiapine, sertindole, and lithium. The antibiotic can be Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim, Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin. Macrolides: Azithromycin, Clarithromycin, Erythromycin, chlortetracycline, procaine, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, vancomycin, virginamycin, and bambermycin. The mode of administration can be oral.
- In another aspect, provided herein is a method of reducing weight gain or reversing weight gain in a human or another mammal. The method can comprise or consist essentially of administering a therapeutically effective amount of reutericyclin-producing strain of Lactobacillus reuterii to reduce weight gain or induce weight loss using a clinically accepted administration route. The reutericyclin-producing strain can be L. reuteri LTH2584. The human or another mammal can be receiving treatment with an antibiotic or xenobiotic. The therapeutically effective amount of reutericyclin can be co-administered with an antibiotic or xenobiotic. The xenobiotic can be an antipsychotic medication. The antipsychotic medication can be selected from the group consisting of risperidone, clozapine, olanzapine, quetiapine, and sertindole. The antibiotic can be Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim, Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin. Macrolides: Azithromycin, Clarithromycin, Erythromycin, chlortetracycline, procaine, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, vancomycin, virginamycin, and bambermycin. The mode of administration can be oral.
- In another aspect, provided herein is a pharmaceutical composition comprising Lactobacillus reuterii LTH2584 or a lysate thereof. The pharmaceutical composition can further comprise a probiotic bacterium of a strain other than L. reuteri LTH2584, or a lysate thereof, and pharmaceutically acceptable carrier. The Lactobacillus reuterii LTH2584 can be present in the composition at a quantity of at least 1,000,000 colony forming units per gram, based upon the total weight of the composition.
- In a further aspect, provided herein is a lysate of Lactobacillus reuterii LTH2584.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference.
- The patent or patent application file contains at least one drawing in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 demonstrates that Lactobacillus reuterii is selectively depleted in risperidone-treated mice. Shotgun metagenomic sequencing data (MiSeq, 2×250, high yield) from stool DNA was analyzed on the Anvi'o visualization platform. Bacterial genomes were refined to either genus or species level and ordered as slices within a ring by gene similarity (hierarchical clustering with a Hidden Markov Model). Metagenome groups enriched following risperidone treatment are indicated (red) relative to controls (blue). -
FIGS. 2A-2C show that supplementation with reutericyclin-producing strain LTH2584 abrogates weight gain in mice. (A) Experimental design: C57Bl/6J female mice arrived at 6 weeks of age and were allowed to acclimate to the facility for two weeks (n=10/group). Baseline stool was collected every other day through 15 weeks where visceral fat tissue was harvested. (B) Shown are body mass increases for control animals (blue), those receiving L. reuteri producing reutericyclin (green), or L. reuteri producing reutericyclin+risperidone (magenta), or L. reuteri unable to produce reutericyclin+risperidone (red). (C) Visceral fat pads were dissected at day 64 from each mouse, weighed, and quantified. Color coding is the same as above inFIG. 2B . Fat pads from risperidone-treated mice that also received L. reuteri capable of producing reutericyclin were significantly reduced relative to those animals that received risperidone treatment alone (Wilcoxon, *p<0.05). -
FIG. 3 . Random Forest model classifies olanzapine-treated mice as well as risperidone based on changes in key taxa. -
FIG. 4 . Linear model (LM) predictions against the actual weight gained for risperidone, reutericyclin, and probiotic treated mice. The randomized training set animals are shown in black and the test set animals are shown in blue. A line of best fit (solid blue line) and the y=x line (black, dashed line) are there for reference. A Spearman rank-order correlation was performed to determine significance of the predicted weights (p=0.000748). -
FIG. 5 . Linear model (LM) predicts the weight gain in olanzapine-treated animals (p<0.00001). -
FIG. 6 . Detection of unique genes in Akkermansia muciniphila found in probiotic-treated animals can be adapted to a PCR-based test for treatment efficacy. - The compositions and methods provided herein are based, at least in part, on the inventors' surprising discovery that reutericyclin, a small molecular weight antimicrobial produced by some strains of Lactobacillus reuteri. The present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing Lactobacillus reuterii bacteria as a probiotic to reduce weight gain or to induce weight loss, particularly for subjects receiving an antibiotic or xenobiotic treatment. Microbes that inhabit the human gastrointestinal (GI) tract are involved in xenobiotic processing, as evidenced by changes in metabolism in the absence of microbes (i.e., germ-free (GF) animals) or upon microbial perturbation (i.e., antibiotic treatment or dietary modulation). Without being bound to any particular theory or mechanism of action, it is believed that supplementation with reutericyclin, an analog thereof, or reutericyclin-producing Lactobacillus reuterii may induce and/or support beneficial weight loss, particularly in subject receiving treatment with an antibiotic or pharmaceutical that alters metabolism and is linked to weight gain or obesity.
- Accordingly, in a first aspect, provided herein are methods of reducing or reversing weight gain or inducing weight loss in a subject. The methods comprise or consist essentially of the step of administering to a patient an amount of reutericyclin effective to inhibit or reverse weight gain. As used herein, the term “reutericyclin” refers to a highly hydrophobic, charged tetramic acid molecule produced by and isolated from particular strains of Lactobacillus reuterii. Referring to the main tautomeric form in solution, reutericyclin is (5R)-1-(2-decenoyl)-2-hydroxy-3-acetyl-5-isobutyl-Δ2-pyrroline-4-one, a N-acylated tetramic acid. N-alkyl reutericyclin analogs have been shown to retain activity against Gram-positive pathogens and other functional properties of reutericyclin. See, e.g., Yendapally et al., J. Med. Chem. 51, 1487-1491 (2008); Hurdle et al., Antimicrob. Agents Chemother. 53, 4028-4031 (2009).
- In some cases, the method comprises administering a therapeutically effective amount of reutericyclin to reduce weight gain or induce weight loss using a clinically accepted administration route.
- In some cases, the subject is being treated with an antibiotic or xenobiotic, including pharmaceuticals for which weight gain is a known side-effect. In some cases, reutericyclin can also be co-administered (e.g., sequentially or simultaneously) with or following administration of such an antibiotic or xenobiotic in order to preserve non-pathological intestinal bacterial flora in the subject to whom the reutericyclin is administered.
- As used herein, the term “xenobiotic” refers to chemical compounds to which an organism (e.g., human, non-human mammal) is exposed that are extrinsic to the normal metabolism of that organism. The term encompasses synthetic drugs, small molecules, natural poisons, food additives, environmental pollutants, antibiotics, and other pharmaceuticals.
- As used herein, the term “antibiotic” refers to a chemotherapeutic substance that is capable of killing and inhibiting growth of specific microorganisms, such as infectious bacteria and fungi. Antibiotics are classified based on their mechanism of action (i.e., if on the cell membrane, cell wall, or metabolism), chemical structure, spectrum of activity (i.e., if targeting gram-negative or gram-positive bacteria), or by mode of administration (e.g. oral, intravenous, or topical).
- The term “reducing” refers to any indicia of success in the prevention or reduction of weight gain in a patient induced by or associated with an antibiotic or xenobiotic medication. The prevention or reduction of weight gain can be measured based on objective parameters, such as the results of a physical examination.
- The term “reversing” refers to any indicia of success in causing the loss of antibiotic- or xenobiotic-associated weight gain established prior to the administration of reutericyclin or an analog thereof. The reduction of weight already gained can be measured based on objective parameters, such as the results of a physical examination.
- Pharmaceuticals known to be associated with weight gain in patients receiving the medication include, without limitation antibiotics, antipsychotic medications (e.g., risperidone, haloperidol, olanzapine, clozapine, quetiapine, sertindole, and lithium), antidepressants (e.g., amitriptyline, paroxetine, and sertraline), oral corticosteroids, and drugs for treating diabetes and pre-diabetes (e.g., pre-diabetic states of impaired glucose tolerance) or its associated complications. In some cases, the methods and compositions provided herein are particularly advantageous to reduce weight gain or reverse weight gain in subjects to whom an antipsychotic medication such as risperidone or another atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. Risperidone has been shown to alter the gut microbiome and suppress non-aerobic resting metabolism in mice receiving the antipsychotic medication (Bahr et al., EBioMedicine 2:1725-1734 (2015)). In particular, Bahr et al. demonstrated that risperidone treatment led to an overall reduction in observed taxa in the gut microbiome and selectively suppressed growth of organisms under anaerobic conditions. Other antipsychotics known to cause weight gain include, without limitation, quetiapine (Seroquel), paliperidone (invega), iloperidone (Fanapt), olanzapine (zyprexa), asenapine (saphris), lurasidone (latuda).
- Antibiotics known to cause weight gain in farm animals and used in animal feed include, without limitation, chlortetracycline, procaine, penicillin, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, virginamycin, and bambermycins.
- Antibiotics known to induce weight gain in mice include, without limitation, chlortetracycline, penicillin, vancomycin, combinations of penicillin and vancomycin, streptomycin, and ciprofloxacin.
- The following antibiotics (listed by category) are correlated with weight gain in humans. These associations have not been established via clinical trials, but are associated with either adult or pediatric exposure to antibiotics and the recipient's risk of developing obesity later in life. Taking any of the antibiotics listed either long term or single dose increases risk of developing obesity by 10-15%. Narrow-spectrum antibiotics: Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim. Broad-spectrum antibiotics: Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin. Macrolides: Azithromycin, Clarithromycin, Erythromycin.
- As used herein, “obesity” means a medical condition in which excess body fat has accumulated to the extent that it may have a negative effect on health. One measurement of body fat is the body mass index (BMI), a measurement that compares weight and height, defines obesity as greater than 30 kg (weight) per m2 (height2). Obesity increases the likelihood of various diseases, particularly heart disease and type 2 diabetes (T2D).
- The methods of this invention inhibit or reverse weight gain, including pharmaceutical-induced weight gain. The amount of reutericyclin or a reutericyclin analog adequate to accomplish this is defined as a “therapeutically effective amount.” As used herein, a “therapeutically effective amount” means an amount of a compound or composition that, when administered to a subject for treating a disorder, condition, or disease, is sufficient to effect such treatment for the disorder, or condition, or disease. The “therapeutically effective amount” will vary depending on the compound or composition, the disorder, or condition, or disease state being treated, the severity or the disorder, or condition, or disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors. The dosage schedule and amounts effective for this use, i.e., the “dosing regimen,” will depend upon a variety of factors, including the type of the medication the patient is using, the amount of pharmaceutical-induced weight gain that has already occurred, the patient's physical status, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.
- In another aspect, provided herein is a probiotic composition including an appropriate quantity of reutericyclin-producing Lactobacillus reuteri bacteria, as well as methods for using the disclosed probiotic composition to induce and sustain weight loss in humans and non-human mammals, such as humans, horses, rats, mice, ruminants, primates, monkeys, hamsters, rabbits, and cats. As used herein, the term “probiotic” refers to a live or dead microbial food supplement which beneficially affects the animal, including human host by improving the individual's microbial balance in the gastrointestinal tract, e.g., Lactobacillus reuteri and other Lactobacillus acidophilus. That is, a probiotic microorganism is useful for changing the digestive system bacteria in animals when fed orally. For example, a probiotic microorganism, upon oral feeding, sustain or increase the population of appropriate Bacteroides bacteria in the gastrointestinal tract of the host. It is believed that successful establishment and propagation of appropriate reutericyclin-producing Lactobacillus reuteri bacteria in the gastrointestinal tract of a subject may induce and/or support beneficial weight loss, particularly in humans. The probiotic microorganism remains effective in the digestive system for substantial periods of time even after oral feeding is discontinued.
- Lactobacillus reuteri is one of the few endogenous Lactobacillus species found in the gastrointestinal tract of vertebrates, including humans, rats, pigs and chickens. Reutericyclin-producing strains of Lactobacillus reuteri suitable for the compositions and methods provided herein include, without limitation, Lactobacillus reuterii LTH2584, Lactobacillus reuterii TMW1.106, Lactobacillus reuterii 1.112, and Lactobacillus reuterii 1.656. Each of these strains was isolated from the same industrial sourdough in 1988, 1994, and 1998, which has been maintained by continuous propagation. In preferred embodiments, the reutericyclin-producing bacteria are L. reuteri LTH2584.
- Also provided herein are methods of administering a probiotic pharmaceutical composition comprising reutericyclin-producing Lactobacillus reuteri bacteria or a lysate thereof. In such cases, probiotic bacteria or their lysates according to the invention may be formulated as pharmaceutical compositions for clinical use and may comprise a pharmaceutically acceptable carrier, diluent or adjuvant. As used herein “lysates” refers to a sample of the probiotic bacterium which has been subject to lysis. A lysate may contain one or more soluble metabolites of the probiotic bacterium useful in the methods described herein. Lysis may occur by chemical or physical disruption, for example by addition of an osmotic agent or enzyme to the bacteria, or by the application of physical pressure, for example through sonic disruption. The lysate may be a mixture comprising the cellular contents of the probiotic bacterium. For example, one or more of fragments of cell wall or cell membrane, proteins, nucleic acids, carbohydrates, and organelles (disrupted or intact). The lysate may be suspended, for example in aqueous medium.
- In some cases, reutericyclin-producing Lactobacillus reuteri bacteria are co-administered with or following administration of an antibiotic or xenobiotic to a subject in need thereof in order to preserve non-pathological intestinal bacterial flora in the subject to whom the reutericyclin-producing L. reuteri are administered.
- In some cases, reutericyclin-producing Lactobacillus reuteri bacteria are provided as a probiotic in foods, medicines for humans and animals, and feedstock. Preferably, such probiotic reutericyclin-producing Lactobacillus reuteri bacteria are used alone, with an appropriate vehicle (carrier), or as an additive to a foodstuff or other composition suitable for human or animal (e.g., livestock, household pets) consumption. That is, the reutericyclin-producing Lactobacillus reuteri bacteria are useful because it can be added both to foodstuffs that do not contain probiotic bacteria (for the purpose of giving these products a probiotic value as well) and to foodstuffs already containing some probiotic bacteria (for the purpose of enhancing and/or completing their probiotic value). As used herein, livestock includes swine, cow, horse, goat, sheep, etc.; poultry includes fowls such as chicken, etc.; and pets include dogs, cats, etc.
- For purposes of the present disclosure, the term “treating” or “treatment” describes the management and care of a patient for the purpose of combating the disease, condition, or disorder. The terms embrace both preventative, i.e., prophylactic, and palliative treatments. Treating includes the administration of a composition as described herein to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- As used herein, “subject” refers to an animal or a patient for whom the described treatment is intended. For example, subjects treated according to the methods provided herein are mammals, including by way of example and not limitation, members of rodentia (e.g., mouse, rat, guinea pig), lagomorpha (e.g., rabbits, hares), perissodactyla (e.g., horses, donkeys, etc.), artodactyla (e.g., pigs, cows, sheep), carnivora (e.g., cats, canines), and primates (e.g., apes, monkeys, baboons, and humans). a rodent (e.g., mouse, rat) or a primate (e.g., a monkey, baboon, human). In exemplary embodiments, the subject is a human. The term “subject” does not denote a particular age or sex. By “subject in need thereof,” we mean an animal or human subject who has been diagnosed with a disease or condition requiring treatment.
- Any appropriate route or mode of administration to the subject can be employed according to a method provided herein. In exemplary embodiments, reutericyclin or reutericyclin-producing bacteria are administered to a subject as a pharmaceutical composition and in an effective amount to treat and/or prevent a disorder (e.g., weight gain) as described herein. In some cases, the pharmaceutical composition comprises probiotic bacteria of the strain Lactobacillus reuterii LTH2584. In some cases, the probiotic bacteria may be provided in the form of a lysate. In some cases, a lysate of probiotic bacteria may be subjected to purification of filtration steps to remove other components, such as bacterial growth media or contaminants.
- As used herein, the term “pharmaceutical composition” refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof, with other chemical components, such as physiologically acceptable carriers and excipients. One purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism. As used herein, a “pharmaceutically acceptable carrier” refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. “Pharmaceutically acceptable salt” refers to those salts that retain the biological effectiveness and properties of the free bases and that are obtained by reaction with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- Pharmaceutically active compositions and dosage forms of the disclosure include a pharmaceutically acceptable salt of disclosed or a pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof. Specific salts of disclosed compounds include, but are not limited to, sodium, lithium, potassium salts, and hydrates thereof. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in Handbook of Pharmaceutical Salts: Properties, and Use (2002), which is incorporated herein by reference. In some cases, compositions can be administered to a subject in need thereof in dosage unit form where each discrete dosage unit contains a predetermined quantity of an active ingredient or compound that was calculated to elicit a desirable therapeutic effect when administered with, in some cases, a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carriers” as used herein refers to carriers, excipients, or stabilizers that are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
- For probiotics, pharmaceutically acceptable carriers are particularly important to protect and preserve the probiotic bacteria until such time that the probiotic bacteria arrive within the gastrointestinal tract of a subject.
- For determining a therapeutically effective dose, it can be advantageous to assess toxicity and therapeutic efficacy of a compound (e.g., reutericyclin or an analog thereof) in an in vitro assay (e.g., cell cultures) or in experimental animals. For example, the LD50 (i.e., the dose lethal to 50% of the population) and ED50 (i.e., the dose therapeutically effective in 50% of the population) can be determined. From these calculations, dosage ranges for use in humans can be formulated. Dosage ranges can vary depending on factors such as mode of administration. A therapeutically effective amount of a pharmaceutical composition provided herein can range from about 0.001 to 100 mg of an active ingredient per kg body weight of the subject (e.g., about 0.001 to 100 mg/kg body weight; about 0.1 to 40 mg/kg body weight; about 1 to 20 mg/kg body weight). In some cases, an appropriate dose of a pharmaceutical composition can be determined according to body surface area of a subject, calculated using the subject's height and weight, to whom the composition will be administered. In such cases, a dose can be provided as a particular amount of the composition per m2 (e.g., mg/m2). In other cases, dosages and dosage ranges appropriate for a composition provided herein can be determined using pharmacokinetic data (i.e., drug metabolism and clearance). As used herein, “pharmacokinetics” refers to the process by which a drug or pharmaceutical composition is absorbed, distributed, metabolized, and excreted from the body. Additional information about dosage calculation can be found in Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2002), Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, U.S. Food and Drug Administration, Rockville, Md., USA.
- As stated above, a therapeutically effective dose level will depend on many factors. In addition, it is well within the skill of the art to start doses of the active composition at relatively low levels, and increase the dosage until the desired effect is achieved. Efficacy of the methods provided herein can be determined using any appropriate method. For example, weight gain may be determined and evaluated with any one of several objective, standard instruments known in the art, which include scales and instruments that measure body fat percentage. The simple instrument of a scale is routinely used by all professional health care practitioners. More sophisticated instruments to measure body fat percentage operate based on skin-fold methodology and measurement of body density or electrical resistance.
- A formulation may contain a single (unit) dose of probiotic bacteria, or lysate thereof. Suitable doses of probiotic bacteria (intact or lysed) may be in the
range 104 to 1012 colony forming units (cfu), e.g. one of 104 to 1010, 104 to 108, 106 to 1012, 106 to 1010, or 106 to 108 cfu. In some embodiments doses may be administered once or twice daily. - Pharmaceutical unit dosage forms of the compounds of this disclosure are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., bolus injection), topical, or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as hard gelatin capsules and soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- The composition, shape, and type of dosage forms of the compositions of the disclosure will typically vary depending on their use. For example, a dosage form used in the acute treatment of a disease or disorder may contain larger amounts of the active ingredient, for example the disclosed compounds or combinations thereof, than a dosage form used in the chronic treatment of the same disease or disorder. Similarly, a parenteral dosage form may contain smaller amounts of the active ingredient than an oral dosage form used to treat the same disease or disorder. These and other ways in which specific dosage forms encompassed by this disclosure will vary from one another will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton, Pa. (1990).
- Clinicians, physicians, and other health care professionals can administer a composition to a subject in need thereof according to a method provided herein. In some cases, a single administration of the composition may be sufficient. In other cases, more than one administration of the composition is performed at various intervals (e.g., once per week, twice per week, daily, monthly) or according to any other appropriate treatment regimen. The duration of treatment can be a single dose or periodic multiple doses for as long as administration of a composition provided herein is tolerated by the subject.
- It is to be understood that this invention is not limited to the particular methodology, protocols, materials, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
- In the specification and in the claims, the terms “including” and “comprising” are open-ended terms and should be interpreted to mean “including, but not limited to . . . .” These terms encompass the more restrictive terms “consisting essentially of” and “consisting of.”
- As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. As well, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, “characterized by” and “having” can be used interchangeably.
- The terms “including”, “such as”, “for example” and the like are intended to refer to exemplary embodiments and not to limit the scope of the present disclosure.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes including describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. All references cited in this specification are to be taken as indicative of the level of skill in the art. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
- These and other features, objects and advantages of the present invention will become better understood from the description that follows. In the description, reference is made to the accompanying drawings, which form a part hereof and in which there is shown by way of illustration, not limitation, embodiments of the invention. The description of preferred embodiments is not intended to limit the invention to cover all modifications, equivalents and alternatives. Reference should therefore be made to the claims recited herein for interpreting the scope of the invention.
- The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and the following examples and fall within the scope of the appended claims.
- To determine whether Lactobacillus reuterii is selectively depleted in risperidone-treated mice, C57bl/6J female mice were treated with risperidone for 60 days. Shotgun metagenomic sequencing data (MiSeq, 2×250, high yield) from stool DNA were analyzed on the Anvi'o visualization platform. Bacterial genomes were refined to either genus or species level and ordered as slices within a ring by gene similarity (hierarchical clustering with a Hidden Markov Model). In
FIG. 1 , metagenomes of risperidone treated mice are colored red and control mice colored blue. As shown inFIG. 1 , C57bl/6J female mice treated with risperidone for 60 days displayed statistically significant weight gain and had statistically significant differences in their bacterial composition. Transfer of fecal or viral fractions from drug treated mice was sufficient to produce enhanced weight gain relative to controls. - To further investigate the effects of risperidone treatment on weight gain, female mice were treated with L. reuteri producing reutericyclin, with or without risperidone treatment. C57Bl/6J female mice arrived at 6 weeks of age and were allowed to acclimate to the facility for two weeks (n=10/group) (
FIG. 2A ). 8-week old C57Bl/6J female mice were treated daily via gavage with 100 μL containing either 3×108 CFUs of Lactobacillus reuterii strain LTH2584 (a reutericyclin-producing strain) or buffer (phosphate buffered saline). Drinking water was supplemented with buffer or risperidone (20 mg/mL). Baseline stool was collected every other day through 15 weeks where visceral fat tissue was harvested.FIG. 2B shows body mass increases for control animals (green), those receiving L. reuteri producing reutericyclin (blue), or L. reuteri producing reutericyclin+risperidone (magenta), or L. reuteri unable to produce reutericyclin+risperidone (red). Animals receiving risperidone only were nearly identical to the red line (data not shown). Weight gain in mice treated with risperidone plus L. reuteri producing reutericyclin (magenta) is abrogated at 64 days of treatment relative to those animals receiving risperidone plus L. reuteri lacking the capability to produce reutericyclin (red) as determined by Wilcoxon (*p<0.05), yet showed some weight gain relative to control animals (green) or bacteria-only treated mice (blue). - Visceral fat pads were dissected at day 64 from each mouse, weighed, and quantified. As shown in
FIG. 2C , fat pads from risperidone treated mice that also received L. reuteri capable of producing reutericyclin were significantly reduced relative to those animals that received risperidone treatment alone (Wilcoxon, *p<0.05). - Discussion. This example demonstrates that treatment with reutericyclin prevents weight gain associated with risperidone treatment. These data suggest that reutericyclin can be developed as a weight loss agent or to prevent or abrogate weight gain associated with some pharmaceutical treatments.
- A set of taxonomic changes that characterize the microbiomes of risperidone-treated animals and reutericyclin-treated animals was identified. Using a machine learning method known as Random Forest (RF), these differences were used to generate a prediction model. The minimal components of the model and their relative importance are shown in
FIG. 3 . This model can also be applied to predict weight gain from other drugs in the second-generation anti-psychotic class, including olanzapine treated animals (AUC=0.95). This result indicates that 1) obesity-causing microbiome changes due to risperidone treatment are also observed to occur in response to other anti-psychotics and 2) either reutericyclin or reutericyclin-producing probiotics (L. reuterii strain LTH2584) may be used to treat obesity from other anti-psychotics. - Using the observed changes above, we generated a linear model to predict the weight gain for risperidone treated animals. It was determined that this linear model predicts the weight gain associated with risperidone use, reutericyclin treatment and probiotic strain LTH2584 treatment (
FIG. 4 , Spearman Rank Order Correlation, p=0.000748). The training and test sets were randomized and separated before performing the model construction and model evaluation. The model was tested on olanzapine-treated animals and it was determined that the model performs equally well to predict the weight gain associated with another anti-psychotic (FIG. 5 Spearman Rank Order Correlation, p<0.00001). The taxa identified to be important in characterizing body weight changes associated with risperidone, reutericyclin treatment, and olanzapine treatment can be adapted to a PCR-based diagnostic to predict treatment response and weight gain. - To increase predictive specificity, we can generate a classifier for treatment response and a linear model of weight gain in response to these treatments (risperidone and reutericyclin) based on gene-specific differences. For example, Akkermansia muciniphila strains have unique 26.1 kb genomic signature in risperidone-treated animals compared to probiotic LTH2584 treated animals. In contrast, Akkermansia muciniphila has a unique 37.8 kb stretch (
FIG. 6 ) in LTH2584 probiotic treated animals. A PCR-based test can be generated to identify these genes in order to determine treatment efficacy. - Lastly, 20 gene reutericyclin synthesis-like gene clusters (blastp, e-value=<0.0005) were identified in human datasets (stool) that were differentially abundant in healthy human controls (n=50) relative to pre-diabetic patients (n=40) that reported weight gain at time of sampling. These genes, as well as other specific gene trends, can be incorporated into a random forest and linear model to predict weight gain in humans. These data suggest that reutericyclin-like molecules may have a role in human weight gain.
- The present invention is not intended to be limited to the foregoing examples, but encompasses all such modifications and variations as come within the scope of the appended claims.
Claims (15)
1. A method of reducing and/or reversing weight gain in a human, the method comprising administering a therapeutically effective amount of reutericyclin to reduce weight gain or induce weight loss; wherein the human is being treated with an antibiotic or xenobiotic.
2. A pharmaceutical composition comprising Lactobacillus reuterii LTH2584 and/or a lysate thereof; and a pharmaceutically acceptable carrier.
3. A pharmaceutical composition comprising an antibiotic or xenobiotic medication; reutericyclin; and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein the composition is formulated to be administered using a clinically accepted administration route.
5. The pharmaceutical composition of claim 3 , wherein the composition is formulated to be administered orally.
6. The pharmaceutical composition of claim 3 , wherein the composition comprises an amount of the reutericyclin, which is therapeutically effective to reduce weight gain and/or induce weight loss.
7. The pharmaceutical composition of claim 3 , wherein the antibiotic is selected from Amoxicillin, Ampicillin, Cefadroxil, Cephalexin, Clindamycin, Loracarbef, Metronidazole, Penicillin, Sulfisoxazole, Trimethroprim, Amoxicillin-Clavulanate, Ampicillin-Sulbactam Azithromycin, Cefoxitin, Ceftazidime, Ceftriaxone, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Cefpodoxime, Cefprozil, Ceftibuten, Cefuroxime, Ciprofloxacin, Doxycycline, Gentamicin, Imipenem, Levofloxacin, Linezolid, Piperacillin-Tazobactam, Sulfamethoxazole-Trimethoprim, Tobramycin, Vancomycin. Macrolides: Azithromycin, Clarithromycin, Erythromycin, chlortetracycline, procaine, oxytetracycline, tylosin, bacitracin, neomycin sulfate, streptomycin, erythromycin, linomycin, oleandomycin, vancomycin, virginamycin, and bambermycin.
8. The pharmaceutical composition of claim 3 , wherein the composition comprises the xenobiotic medication, which comprises an antipsychotic medication.
9. The pharmaceutical composition of claim 8 , wherein the composition comprises an amount of reutericyclin, which is therapeutically effective to reduce weight gain and/or induce weight loss.
10. The pharmaceutical composition of claim 8 , wherein the composition comprises an atypical antipsychotic medication.
11. The pharmaceutical composition of claim 10 , wherein the atypical antipsychotic medication is olanzapine.
12. The pharmaceutical composition of claim 8 , wherein the antipsychotic medication is selected from the group consisting of risperidone, clozapine, olanzapine, quetiapine, and sertindole.
13. The pharmaceutical composition of claim 8 , wherein the composition is formulated to be administered orally; and the antipsychotic medication is risperidone.
14. The pharmaceutical composition of claim 8 , wherein the composition comprises a benzisoxazole antipsychotic medication.
15. The pharmaceutical composition of claim 14 , wherein the benzisoxazole antipsychotic medication is risperidone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/393,000 US20210361621A1 (en) | 2018-07-16 | 2021-08-03 | Compositions and Methods for Reducing Weight Gain |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862698601P | 2018-07-16 | 2018-07-16 | |
US16/511,630 US11116748B2 (en) | 2018-07-16 | 2019-07-15 | Compositions and methods for reducing weight gain |
US17/393,000 US20210361621A1 (en) | 2018-07-16 | 2021-08-03 | Compositions and Methods for Reducing Weight Gain |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/511,630 Continuation US11116748B2 (en) | 2018-07-16 | 2019-07-15 | Compositions and methods for reducing weight gain |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210361621A1 true US20210361621A1 (en) | 2021-11-25 |
Family
ID=67480411
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/511,630 Active 2039-12-25 US11116748B2 (en) | 2018-07-16 | 2019-07-15 | Compositions and methods for reducing weight gain |
US17/393,000 Pending US20210361621A1 (en) | 2018-07-16 | 2021-08-03 | Compositions and Methods for Reducing Weight Gain |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/511,630 Active 2039-12-25 US11116748B2 (en) | 2018-07-16 | 2019-07-15 | Compositions and methods for reducing weight gain |
Country Status (11)
Country | Link |
---|---|
US (2) | US11116748B2 (en) |
EP (1) | EP3823724A1 (en) |
JP (1) | JP2021530512A (en) |
KR (1) | KR20210032421A (en) |
CN (1) | CN112423842A (en) |
AU (1) | AU2019308183A1 (en) |
BR (1) | BR112021000035A2 (en) |
CA (1) | CA3105723A1 (en) |
IL (1) | IL280050A (en) |
MX (1) | MX2021000426A (en) |
WO (1) | WO2020018420A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012032360A2 (en) * | 2010-09-10 | 2012-03-15 | Helperby Therapeutics Limited | Novel use |
WO2012050826A1 (en) * | 2010-09-29 | 2012-04-19 | St. Jude Children's Research Hostpital | Methods for treating clostridium difficile infections |
US20150238473A1 (en) * | 2012-09-27 | 2015-08-27 | University Of Rochester | Methods and compositions for treating infection |
US20190125825A1 (en) * | 2017-10-12 | 2019-05-02 | High Point University | Small-molecule adjuvants for antibiotics to address antibiotic resistance |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120015335A (en) * | 2009-05-01 | 2012-02-21 | 마이크로파마 리미티드 | Bacterial compositions for prophylaxis and treatment of degenerative disease |
-
2019
- 2019-07-15 CA CA3105723A patent/CA3105723A1/en not_active Abandoned
- 2019-07-15 WO PCT/US2019/041803 patent/WO2020018420A1/en unknown
- 2019-07-15 CN CN201980047302.5A patent/CN112423842A/en active Pending
- 2019-07-15 KR KR1020217003915A patent/KR20210032421A/en unknown
- 2019-07-15 EP EP19746343.3A patent/EP3823724A1/en active Pending
- 2019-07-15 BR BR112021000035-6A patent/BR112021000035A2/en not_active Application Discontinuation
- 2019-07-15 MX MX2021000426A patent/MX2021000426A/en unknown
- 2019-07-15 JP JP2021502423A patent/JP2021530512A/en active Pending
- 2019-07-15 AU AU2019308183A patent/AU2019308183A1/en not_active Abandoned
- 2019-07-15 US US16/511,630 patent/US11116748B2/en active Active
-
2021
- 2021-01-10 IL IL280050A patent/IL280050A/en unknown
- 2021-08-03 US US17/393,000 patent/US20210361621A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012032360A2 (en) * | 2010-09-10 | 2012-03-15 | Helperby Therapeutics Limited | Novel use |
WO2012050826A1 (en) * | 2010-09-29 | 2012-04-19 | St. Jude Children's Research Hostpital | Methods for treating clostridium difficile infections |
US20150238473A1 (en) * | 2012-09-27 | 2015-08-27 | University Of Rochester | Methods and compositions for treating infection |
US20190125825A1 (en) * | 2017-10-12 | 2019-05-02 | High Point University | Small-molecule adjuvants for antibiotics to address antibiotic resistance |
Also Published As
Publication number | Publication date |
---|---|
EP3823724A1 (en) | 2021-05-26 |
MX2021000426A (en) | 2021-03-25 |
AU2019308183A1 (en) | 2021-01-28 |
IL280050A (en) | 2021-03-01 |
CN112423842A (en) | 2021-02-26 |
CA3105723A1 (en) | 2020-01-23 |
KR20210032421A (en) | 2021-03-24 |
BR112021000035A2 (en) | 2021-04-06 |
JP2021530512A (en) | 2021-11-11 |
US20200016124A1 (en) | 2020-01-16 |
US11116748B2 (en) | 2021-09-14 |
WO2020018420A1 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sequeira et al. | Commensal Bacteroidetes protect against Klebsiella pneumoniae colonization and transmission through IL-36 signalling | |
Spencer et al. | The innate immune response during urinary tract infection and pyelonephritis | |
Lau et al. | Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial | |
Trombone et al. | Periodontitis and arthritis interaction in mice involves a shared hyper-inflammatory genotype and functional immunological interferences | |
Pena Cortes et al. | Development of the tonsillar microbiome in pigs from newborn through weaning | |
US20230158085A1 (en) | Inhibition of enteric infection through the modulation of microbiota | |
Fleury et al. | Impact of two different colistin dosing strategies on healthy piglet fecal microbiota | |
Kulkarni et al. | Cigarette smoke extract–exposed methicillin-resistant Staphylococcus aureus regulates leukocyte function for pulmonary persistence | |
Heimesaat et al. | The role of IL-23, IL-22, and IL-18 in Campylobacter jejuni infection of conventional infant mice | |
Fabian et al. | Intestinal colonization of genotoxic Escherichia coli strains encoding colibactin and cytotoxic necrotizing factor in small mammal pets | |
US11116748B2 (en) | Compositions and methods for reducing weight gain | |
Grilló et al. | Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice | |
Drider et al. | Impact of colistin and colistin-loaded on alginate nanoparticles on pigs infected with a colistin-resistant enterotoxigenic Escherichia coli strain | |
Kimura et al. | Decreasing the abundance of tetracycline-resistant Escherichia coli in pig feces during nursery using flavophospholipol as a pig feed additive | |
US20220202879A1 (en) | Compositions and methods of treating asthma | |
Harp | Cryptosporidium and host resistance: historical perspective and some novel approaches | |
Abu-Basha et al. | Comparative pharmacokinetics of gentamicin after intravenous, intramuscular, subcutaneous and oral administration in broiler chickens | |
Carlier et al. | A severe case of pneumopathy in a duck breeder due to Chlamydia psittaci diagnosed by 16S rDNA sequencing | |
US20210106572A1 (en) | Use of pridopidine for the treatment of anxiety and depression | |
Kromann et al. | Treatment with high-dose antidepressants severely exacerbates the pathological outcome of experimental Escherichia coli infections in poultry | |
Weese et al. | Suspected ciprofloxacin‐induced colitis in four horses | |
CN114375200A (en) | Medicament and method for treating infectious diseases | |
Adekunle et al. | Antimicrobial resistance and plasmid profiles of Campylobacter species from infants presenting with diarrhoea in Osun state, Nigeria | |
Roels et al. | Isolation of Morganella morganii from a domestic rabbit with bronchopneumonia | |
US20220340955A1 (en) | Methods for diagnosing and treatment monitoring of adnp-deficient patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE MEDICAL COLLEGE OF WISCONSIN, INC., WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIRBY, JOHN RICHARD;DE LEON, ORLANDO GRAJO;REEL/FRAME:057132/0747 Effective date: 20190725 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |